XSHE
000908
Market cap1.55bUSD
Oct 09, Last price
6.02CNY
1D
2.21%
1Q
-10.81%
Jan 2017
-42.39%
Name
Hunan Jingfeng Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hunan Jingfeng Pharmaceutical Co.,Ltd., established in 2003 and headquartered in Shanghai, China, operates as a manufacturer and supplier of various pharmaceutical products, including chemical compounds and biological agents, within the Chinese market. A prominent offering from the company is its sodium hyaluronate injection, which finds extensive application in both orthopedic and surgical fields. Beyond this, their product range encompasses ophthalmology solutions and Active Pharmaceutical Ingredients (APIs). The firm also dedicates resources to the research and development of medications for anti-tumor, cancer, and cardiovascular conditions, alongside providing a selection of skincare products.
Key people
Shulin Liu
President, Director · since 2025
Li Zhang
Acting Chairman of the Board, Acting Secretary of the Board · since 2024
Qizhi Lian
Director · since 2025
Xuehong Ma
Finance Director, Director · since 2024
Dong Yang
President, Director · since 2024
Gaojing Ye
Director · since 2024
Ting Liu
Independent Director
Yimin Xu
Independent Director · since 2024
Shaoxian Zhong
Independent Director
Headquarters & legal address
上海市宝山区罗新路50号
岳阳市, HN 414005
CN
岳阳市, HN 414005
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||